The international standard protocol for acute lymphoblastic leukaemia (ALL) 
Introduction
Acute lymphoblastic leukaemia (ALL) is the most common malignancy in children and it is associated with an overall event-free survival of around 80% at 5 years, being the most successful story of modern multi-agent chemotherapy. Short and long-term cardiovascular complications
Original research article DOI: 10.1515 DOI: 10. /rrlm-2017 are well-known side effects of anthracyclines (AC). These include arrhythmias, myocardial ischemia, hypertension, acute heart failure and ventricular dysfunction.
Chemotherapy-induced cardiotoxicity can be divided into three categories: acute, early and late-onset progressive cardiomyopathy [1] .
The acute type appears within one week of AC administration in less than 1% of the patients. The second form occurs during the first year after treatment in 1.6-2.1%, while the third type develops after this period. It is estimated that 65% of cancer survivors present signs of cardiac damage 6 years after treatment [1] .
Doxorubicin is more toxic than epirubicin [2] . AC-induced cardiac injury is dose dependent and the international recommendations are not to exceed 450-550 mg/m² [3] , although even lower doses have led to cardiac damage in certain patients [4] . The gold standard for cardiotoxicity detection is serial echocardiography, used prior to treatment initiation and during the course of chemotherapy [5] . Cardiac biomarkers (troponin T, troponin I (TnI), natriuretic peptides, high-sensitivity C reactive protein, glycogen phosphorylase isoenzyme BB, heart-type fatty acid binding protein (H-FABP), myeloperoxidase, total antioxidant status, circulating microRNAs, creatinine kinase) represent an attractive alternative for the detection of cardiotoxicity and are intensively analysed for many advantages such as being operator-independent, non-invasive and a resource-efficient approach [4] .
Objective
The purpose of this paper was to monitor TnI and H-FABP levels in children diagnosed with ALL, who received a low-dose of AC.
Patients and Methods
Patients 1 to 18 years of age, newly diagnosed with ALL and treated according to BFM-ALL IC 2002 protocol, were included in this study, after approval from Fundeni Clinical Institute Ethics Committee. Patients were stratified into three treatment groups: standard risk (SR), intermediary risk (IR) and high risk (HR). After signing an informed consent form, blood for biomarkers analysis was obtained at 5 different moments: (T1) at diagnosis (baseline-TnI1, H-FABP1), (T2) one hour after the first AC administration (TnI2, H-FABP2), (T3) before the last AC administration (TnI3, H-FABP3), (T4) one hour after the last AC administration (TnI4, H-FABP4) and (T5) one year after diagnosis (TnI5, H-FABP5).
The cumulative dose (CD) of AC at certain moments was different: at (T2) all patients received CD of 30 mg/m², at (T3) SR and IR patients received CD of 210 mg/m² and HR patients received 270 mg/m², at (T4) SR and IR patients received CD of 240 mg/m² and HR patients received 300 mg/m². In a few cases, AC dose was decreased due to low neutrophil count.
Second generation TnI was assayed on Tosoh Bioscience, AIA-1800 (Immunoassay), with normal range values being 0-0.05 pg/dl.
H-FABP was analysed on calibrated ELISA plate reader using the human H-FABP kit for ELISA (Hycult biotech), the normal range being 0-1.6 ng/ml.
The study was prospective. Characteristics of the study population and biomarker levels were summarized using median, average and range. The statistical analysis was performed using SPSS Statistics 24. Regarding power analysis, we considered a p-value less than 0.05 to be significant, less than 0.001 to be strongly significant and a p less than 0.0001 to indicate highly statistical value. The data were analysed with Shapiro Wilk normality test. We performed parametric tests: average and median values, standard deviation, paired t-test, one-way Anova and Pearson correlation.
Results
The clinical and biological characteristics of the 20 patients included in our study, between February 2015 and April 2016, are presented in TABLE 1.
Most of these features are consistent with the data provided in international studies regarding paediatric patients with ALL. Analysing the age and the leucocyte count using Shapiro Wilk normality test, the results showed that the values were normally distributed. The particularity of our cohort was the high incidence of TEL-AML1 mutation gene (40%) and the stratification of our patients only in SR and IR groups. These aspects were found only in children enrolled until April 2016 and analysed in this paper. From May 2016, the patients' characteristics changed: the incidence of TEL-AML1 decreased significantly, many new patients presented BCR-ABL1 and were assigned to the HR group.
TnI levels are detailed in TABLE 2. We performed a Shapiro Wilk normality test on these data: TnI2 was statistically different from the normal distribution, whereas the other measurements proved to be normally distributed. The troponin levels before and after the first dose of AC were the same (TnI 1 vs TnI 2), but we observed a significant difference before and after the last dose of AC (TnI 3 vs TnI 4, p value 0.039). There was a highly statistical increase between baseline and TnI level after the last dose We divided the CD values into 3 groups: 1-less than 190 mg/m², 2-between 190 and 210 mg/m², 3-between 210 and 240 mg/m². We analysed TnI 4 and TnI 5 measurements by using one-way Anova, taking into consideration the three CD groups, but the results were not significant (f=0.774 and p=0.477, respectively f=0.273 and p=0.765). Performing Pearson correlation between TnI 4 and CD (mg/m²), we obtained a positive, but weak correlation (0.276, p 0.239).
Pearson correlation between Tn4-age and Tn4-number of leucocytes at diagnosis was not statistically significant.
The measurements for H-FABP are detailed in TABLE 3. There was no significant variance immediately after administration of AC 
Discussion
The first documentation of cardiotoxicity in patients with ALL was in 1967 and since then, studies have shown that the relative risk of developing cardiotoxicity increases concurrent to the CD of AC [6] . After exposure to 151-200 mg/m² AC, it is associated with odds ratio of 3.69; between 201-250 mg/m² it doubles (odds ratio 7.23) and, when the total dose of doxorubicin rises above 251 mg/m², the odds ratio reaches 23.47 [7] .
It is essential to identify early-on any signs of cardiac damage in patients undergoing chemotherapy for ALL and in long-term survivals. Biomarkers are valuable tools in the detection of early-onset cardiac toxicity, being able to assist in the evaluation of low-risk patients and, sometimes, they are considered to have a higher sensitivity to detect cardiac injury than echocardiography.
Troponin is considered the best characterized marker for evaluation of cardiac injury after doxorubicin-based treatment in patients with ALL. In 2004, the FDA concluded that TnI is a sensitive, specific and robust biomarker for cardiac damage, allowing the detection and quantification of cellular damage and death [8] . TnI levels have been shown to increase progressively after more AC doses, being associated with a significantly higher risk of left ventricular dysfunction [5] . Given the low elevations of troponin levels that occur after doxorubicin administration, some studies believe that they may represent physiologic variations [8] . There is no general consensus regarding the use of TnI in detecting and monitoring cardiotoxicity in paediatric patients with ALL.
In our cohort, TnI had the same value at baseline and at one hour after the first dose of AC (30mg/m²); we obtained a statistical significant increase in TnI before and one hour after the last dose of doxorubicin (p=0.039), showing that the cardiac damage was more evident as the cumulative dose increases. Moreover, we found a very significant elevation in TnI at the end of all doxorubicin doses compared to baseline levels (p<0.0001). We performed Pearson correlation, between TnI 4 and CD, resulting in a positive, but weak value, showing that the troponin level was directly proportional with the cumulative dose of doxorubicin given throughout the treatment course. We also performed one-way Anova for TnI4 and TnI5, which returned an insignificant result, suggesting that TnI levels do not vary among the 3 CD intervals. All these can be explained by the low dose of AC used in children's protocol, but also by the small number of patients enrolled in the study. In 16 cases (80%), the TnI5 was lower than TnI4, suggesting regeneration of myocytes after the cessation of AC administration (p=0.02).
There are very few studies regarding H-FABP. It is a low molecular weight protein, found in the cytosol, and it has been more recently developed as cardiac biomarker [9, 10, 11] . It can be detected as soon as one hour after onset of ischemia and it can be seen as the earliest plasma marker available [12] . In several studies, no correlation between the risk of cardiotoxicity and elevation of H-FABP was found. We did not find a significant increase in H-FABP immediately after doxorubicin administration, after the total dose of AC, nor after one year after diagnosis.
Conclusion
Cardiac side effects of chemotherapy represent an important evaluation point in ALL patients. Even though the number of children analysed in this paper is small, it is significant for the paediatric patients with ALL treated in our Department.
In this study, we found troponin levels to be correlated with the administration of AC: the value measured after all the AC doses was significantly higher than the baseline. Furthermore, after only four months, the troponin level decreased to the initial value, suggesting there was no permanent damage in cardiac myocytes. Meanwhile, H-FABP does not appear to be useful to detect or monitor doxorubicin-induced cardiotoxicity; therefore, we decided to stop the evaluation of this biomarker in our patients. The study is still open, there are 70 patients enrolled that are being monitored for cardiac damage through changes in TnI levels.
Although clinical manifestations of cardiotoxicity were not encountered in our patients, troponin test should be performed at diagnosis, to define a baseline, and during reinduction to establish the patients at risk of developing cardiac damage. Moreover, patients with increased TnI levels during treatment should be carefully monitored further, in order to detect signs of chronic cardiotoxicity. Because the optimal schedule of biomarker assessments remains unknown, prospective clinical trials are needed. 
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